Showing results (21-30 of 181) with videos related to

Sort By:
Pageof 19
Pharmacogenomics|November 27, 2015
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practiceBruce R Schackman, David W Haas, Sanghee S Park, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 23, 2003
Oxidant stress is increased during treatment of human immunodeficiency virus infectionTodd Hulgan, Jason Morrow, Richard T D'Aquila, et al.
Southern African Journal of HIV Medicine|May 19, 2021
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluidEric H Decloedt, Phumla Z Sinxadi, Lubbe Wiesner, et al.
AIDS (London, England)|May 15, 2019
GCH1 haplotypes and cardiovascular risk in HIVJames E Slaven, David W Haas, Ziyue Liu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 14, 2009
Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal studyMichael S Boger, Ayumi Shintani, Leigh Anne Redhage, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2013
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady statePatty Fan-Havard, Zhongfa Liu, Monidarin Chou, et al.
British Journal of Clinical Pharmacology|September 11, 2012
Neuropsychometric correlates of efavirenz pharmacokinetics and pharmacogenetics following a single oral doseDaniel H Johnson, Tebeb Gebretsadik, Ayumi Shintani, et al.
Plos Biology|July 15, 2004
HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cellsKyra Oswald-Richter, Stacy M Grill, Nikki Shariat, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|December 9, 2017
Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expressionBinglan Li, Shefali S Verma, Yogasudha C Veturi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 9, 2003
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials GroupJohn Spritzler, Donna Mildvan, Aleksandra Russo, et al.
Pageof 19